Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$43M
- −73.6% YoY · −4.7% QoQ
- EPS (diluted)
- −$0.74
- −37.0% YoY · −5.7% QoQ
Source: XBRL data from the CAPRICOR THERAPEUTICS, INC. (CAPR) Q3 2026 10-Q on SEC EDGAR. USD.
CAPRICOR THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no commercial products approved
- Net loss $42.7M vs $24.6M YoY, R&D expense $29.6M vs $20.4M
- Deramiocel spending $11.5M vs $7.3M, exosome research $0.7M vs $1.5M
- Cash, equivalents, restricted cash and securities $198.5M vs $318.1M at December 31, 2025
- FDA PDUFA date November 22, 2026, with additional funding needs and regulatory uncertainty ahead
Risk Factors
- FDA Ad-Com vote 3-9 against Deramiocel effectiveness, extending PDUFA target date to November 22, 2026
- NS arbitration, outcome could determine U.S. distribution rights and impose substantial costs
- Premature commercialization and compliance spending, with new programs addressing Anti-Kickback and False Claims laws
- No FDA-approved products, creating near-term launch and market-acceptance risk
- Potential revenue concentration in Nippon Shinyaku, holding exclusive Deramiocel rights in the United States and Japan
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CAPRICOR THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.